The market for clinical cell selection will reach $1 billion by 2030. Tune in as Smeal alumnus Ted Liberti ’03 M.S., CBO of BioMagnetic Solutions, discusses how his biotech startup's magnetic cell selection technology gives companies the tools to create cures for cancer as cell & gene therapy companies make genetically-engineered CAR-T cells for patients - the future of biotechnology. He discusses how and why he chose to bring his business to State College, and how his company is partnering with Penn State on this important research. #WeAre

"If successful, CAR-T cell and gene therapies (CGT) products are a one & done treatment/Tx/therapy that lives, endures, and continues to deliver its benefits long term, providing bona fide cures in some cases – a word oncologists never use lightly.”
–Ted Liberti